FULL TEST BANK
PHARMACOTHERAPEUTICS FOR ADVANCED PRACTICE NURSE
PRESCRIBERS SIXTH EDITION BY TERI MOSER WOO| WENDY L.
WRIGHT| ALL CHAPTERS INCLUDED( 1-57)|100% VERIFIED
ANSWERS| LATEST EDITION
PRINTED PDF| ORIGINAL DIRECTLY FROM THE PUBLISHER| 100% VERIFIED ANSWERS| DOWNLOAD
IMMEDIETLY AFTER THE ORDER
,Table of Contents
UNIT I. THE FOUNDATION ............................................................................................................................ 4
CHAPTER 1. THE ROLE OF THE NURSE PRACTITIONER AS PRESCRIBER .................................................... 4
CHAPTER 2. REVIEW OF THE BASIC PRINCIPLES OF PHARMACOLOGY ................................................... 23
CHAPTER 3. RATIONAL DRUG SELECTION ............................................................................................... 32
CHAPTER 4. LEGAL AND PROFESSIONAL ISSUES IN PRESCRIBING .......................................................... 36
CHAPTER 5. ADVERSE DRUG REACTIONS ................................................................................................ 39
CHAPTER 6. AN INTRODUCTION TO PHARMACOGENETICS ................................................................... 44
CHAPTER 7. NUTRITION AND NUTRACEUTICALS .................................................................................... 48
CHAPTER 8. HERBAL THERAPIES ............................................................................................................. 58
CHAPTER 9. CANNABIS............................................................................................................................ 66
CHAPTER 10. PHARMACOECONOMICS ................................................................................................... 74
UNIT II. PHARMACOTHERAPEUTICS WITH SINGLE DRUGS ........................................................................ 78
CHAPTER 11. DRUGS AFFECTING THE AUTONOMIC NERVOUS SYSTEM ................................................ 79
CHAPTER 12. DRUGS AFFECTING THE CENTRAL NERVOUS SYSTEM ...................................................... 90
CHAPTER 13. DRUGS AFFECTING THE CARDIOVASCULAR AND RENAL SYSTEMS................................. 102
CHAPTER 14. DRUGS AFFECTING THE RESPIRATORY SYSTEM .............................................................. 114
CHAPTER 15. DRUGS AFFECTING THE HEMATOLOGICAL SYSTEM ....................................................... 120
CHAPTER 16. DRUGS AFFECTING THE IMMUNE SYSTEM: IMMUNIZATIONS ....................................... 127
CHAPTER 17: DRUGS AFFECTING THE IMMUNE SYSTEM: IMMUNOMODULATORS ............................ 134
CHAPTER 18. DRUGS AFFECTING THE GASTROINTESTINAL SYSTEM .................................................... 150
CHAPTER 19. DRUGS AFFECTING THE ENDOCRINE SYSTEM: PANCREATIC HORMONES AND
ANTIDIABETIC DRUGS ........................................................................................................................... 155
CHAPTER 20. DRUGS AFFECTING THE ENDOCRINE SYSTEM: PITUITARY, THYROID, AND ADRENAL
DRUGS ................................................................................................................................................... 162
CHAPTER 21. DRUGS AFFECTING THE REPRODUCTIVE SYSTEM ........................................................... 179
CHAPTER 22. DRUGS AFFECTING THE BONES AND JOINTS .................................................................. 187
CHAPTER 23. DRUGS AFFECTING THE INTEGUMENTARY SYSTEM ....................................................... 195
CHAPTER 24. DRUGS USED TO TREAT BACTERIAL DISEASES ................................................................ 202
CHAPTER 25. DRUGS USED TO TREAT VIRAL, FUNGAL, AND PROTOZOAL INFECTIONS....................... 210
CHAPTER 26. DRUGS USED TO TREAT INFLAMMATORY PROCESSES ................................................... 220
CHAPTER 27. DRUGS USED TO TREAT EYE AND EAR DISORDERS ......................................................... 226
UNIT III. PHARMACOTHERAPEUTICS WITH MULTIPLE DRUGS ................................................................ 229
, CHAPTER 28. ANEMIA ........................................................................................................................... 229
CHAPTER 29. ANXIETY AND DEPRESSION ............................................................................................. 234
CHAPTER 30. ATTENTION DEFICIT HYPERACTIVITY DISORDER ............................................................. 239
CHAPTER 31. ASTHMA AND ALERGY..................................................................................................... 243
CHAPTER 32. CHRONIC OBSTRUCTIVE PULMONARY DISEASE.............................................................. 248
CHAPTER 33. CONTRACEPTION............................................................................................................. 259
CHAPTER 34. COVID-19: ACUTE AND CHRONIC .................................................................................... 263
CHAPTER 35. DERMATOLOGICAL CONDITIONS .................................................................................... 281
CHAPTER 36. DIABETES MANAGEMENT ............................................................................................... 286
CHAPTER 37. GASTROESOPHAGEAL REFLUX AND PEPTIC ULCER DISEASE .......................................... 297
CHAPTER 38. HEADACHES ..................................................................................................................... 302
CHAPTER 39. HEART FAILURE ............................................................................................................... 307
CHAPTER 40. HUMAN IMMUNODEFICIENCY VIRUS DISEASE AND ACQUIRED IMMUNODEFICIENCY
SYNDROME ........................................................................................................................................... 314
CHAPTER 41. MENOPAUSAL HORMONE THERAPY .............................................................................. 318
CHAPTER 42. HYPERLIPIDEMIA ............................................................................................................. 329
CHAPTER 43. HYPERTENSION ............................................................................................................... 335
CHAPTER 44. HYPERTHYROIDISM AND HYPOTHYROIDISM .................................................................. 341
CHAPTER 45. OBESITY ........................................................................................................................... 346
CHAPTER 46. PAIN MANAGEMENT: ACUTE AND CHRONIC PAIN ......................................................... 361
CHAPTER 47. PNEUMONIA ................................................................................................................... 366
CHAPTER 48. SEXUALLY TRANSMITTED DISEASES AND VAGINITIS....................................................... 369
CHAPTER 49. SUBSTANCE USE DISORDER............................................................................................. 375
CHAPTER 50. TUBERCULOSIS ................................................................................................................ 385
CHAPTER 51. UPPER RESPIRATORY INFECTION, PHARYNGITIS, SINUSITIS, OTITIS MEDIA, AND OTITIS
EXTERNA ............................................................................................................................................... 388
CHAPTER 52. URINARY TRACT INFECTION ............................................................................................ 392
UNIT IV. SPECIAL DRUG TREATMENT CONSIDERATIONS ......................................................................... 396
CHAPTER 53: WOMEN AS PATIENTS ..................................................................................................... 396
CHAPTER 54. MEN AS PATIENTS ........................................................................................................... 402
CHAPTER 55. PEDIATRIC PATIENTS ....................................................................................................... 405
CHAPTER 56. TRANSGENDERED CLIENTS AS PATIENTS ........................................................................ 409
CHAPTER 57. GERIATRIC PATIENTS ....................................................................................................... 415
,UNIT I. THE FOUNDATION
CHAPTER 1. THE ROLE OF THE NURSE PRACTITIONER AS PRESCRIBER
MULTIPLE CHOICE
IDENTIFY THE CHOICE THAT BEST COMPLETES THE STATEMENT OR ANSWERS THE QUESTION.
1. NURSE PRACTITIONER PRESCRIPTIVE AUTHORITY IS REGULATED BY:
A. THE NATIONAL COUNCIL OF STATE BOARDS OF NURSING
B. THE U.S. DRUG ENFORCEMENT ADMINISTRATION
C. THE STATE BOARD OF NURSING FOR EACH STATE
D. THE STATE BOARD OF PHARMACY
ANSWER>>C
2. THE BENEFITS TO THE PATIENT OF HAVING AN ADVANCED PRACTICE REGISTERED NURSE (APRN)
PRESCRIBER INCLUDE:
A. NURSES KNOW MORE ABOUT PHARMACOLOGY THAN OTHER PRESCRIBERS BECAUSE THEY TAKE IT
BOTH IN THEIR BASIC NURSING PROGRAM AND IN THEIR APRN PROGRAM.
B. NURSES CARE FOR THE PATIENT FROM A HOLISTIC APPROACH AND INCLUDE THE PATIENT IN
DECISION MAKING REGARDING THEIR CARE.
C. APRNS ARE LESS LIKELY TO PRESCRIBE NARCOTICS AND OTHER CONTROLLED SUBSTANCES.
D. APRNS ARE ABLE TO PRESCRIBE INDEPENDENTLY IN ALL STATES, WHEREAS A PHYSICIAN'S ASSISTANT
NEEDS TO HAVE A PHYSICIAN SUPERVISING THEIR PRACTICE.
ANSWER>>B
3. CLINICAL JUDGMENT IN PRESCRIBING INCLUDES:
A. FACTORING IN THE COST TO THE PATIENT OF THE MEDICATION PRESCRIBED
B. ALWAYS PRESCRIBING THE NEWEST MEDICATION AVAILABLE FOR THE DISEASE PROCESS
C. HANDING OUT DRUG SAMPLES TO POOR PATIENTS
D. PRESCRIBING ALL GENERIC MEDICATIONS TO CUT COSTS
ANSWER>>A
4. CRITERIA FOR CHOOSING AN EFFECTIVE DRUG FOR A DISORDER INCLUDE:
, A. ASKING THE PATIENT WHAT DRUG THEY THINK WOULD WORK BEST FOR THEM
B. CONSULTING NATIONALLY RECOGNIZED GUIDELINES FOR DISEASE MANAGEMENT
C. PRESCRIBING MEDICATIONS THAT ARE AVAILABLE AS SAMPLES BEFORE WRITING A
PRESCRIPTION
D. FOLLOWING U.S. DRUG ENFORCEMENT ADMINISTRATION GUIDELINES FOR
PRESCRIBING
ANSWER>>B
5. NURSE PRACTITIONER PRACTICE MAY THRIVE UNDER HEALTH-CARE REFORM BECAUSE OF:
A. THE DEMONSTRATED ABILITY OF NURSE PRACTITIONERS TO CONTROL COSTS
AND IMPROVE PATIENT OUTCOMES
B. THE FACT THAT NURSE PRACTITIONERS WILL BE ABLE TO PRACTICE
INDEPENDENTLY
C. THE FACT THAT NURSE PRACTITIONERS WILL HAVE FULL REIMBURSEMENT
UNDER HEALTHCARE REFORM
D. THE ABILITY TO SHIFT ACCOUNTABILITY FOR MEDICAID TO THE STATE LEVEL
ANSWER>>A
6. AN NP WOULD PRESCRIBE THE LIQUID FORM OF IBUPROFEN FOR A 6-YEAR-OLD CHILD BECAUSE:
A. DRUGS GIVEN IN LIQUID FORM ARE LESS IRRITATING TO THE STOMACH.
B. A 6-YEAR-OLD CHILD MAY HAVE PROBLEMS SWALLOWING A PILL.
C. LIQUID FORMS OF MEDICATION ELIMINATE THE CONCERN FOR FIRST-PASS EFFECT.
D. LIQUID IBUPROFEN DOES NOT HAVE TO BE DOSED AS OFTEN AS THE TABLET FORM
ANSWER>>B
7. IN DECIDING WHICH OF MULTIPLE DRUGS USED TO USE TO TREAT A CONDITION, THE NP CHOOSES
DRUG BECAUSE IT:
A. HAS SERIOUS SIDE EFFECTS AND IT IS NOT BEING USED FOR A LIFE-THREATENING CONDITION
B. WILL BE TAKEN TWICE DAILY AND WILL BE TAKEN AT HOME
C. IS EXPENSIVE, BUT COVERED BY HEALTH INSURANCE
D. NONE OF THESE ARE IMPORTANT IN CHOOSING A DRUG
ANSWER>>B
, 8. A CLIENT ASKS THE NP ABOUT THE DIFFERENCES IN DRUG EFFECTS BETWEEN MEN AND WOMEN.
WHAT IS KNOWNABOUT THE DIFFERENCES BETWEEN THE PHARMACOKINETICS OF MEN AND WOMEN?
A. BODY TEMPERATURE VARIES BETWEEN MEN AND WOMEN.
B. MUSCLE MASS IS GREATER IN WOMEN.
C. PERCENTAGE OF FAT DIFFERS BETWEEN GENDERS.
D. PROVEN SUBJECTIVE FACTORS EXIST BETWEEN THE GENDERS
ANSWER>>C
9. THE FIRST STEP IN THE PRESCRIBING PROCESS ACCORDING TO THE WORLD HEALTH ORGANIZATION
IS:
A. 1.CHOOSING THE TREATMENT
B. 2.EDUCATING THE PATIENT ABOUT THE MEDICATION
C. 3.DIAGNOSING THE PATIENT'S PROBLEM
D. 4.STARTING THE TREATMENT
ANSWER>>C
10. TREATMENT GOALS IN PRESCRIBING SHOULD:
A. 1.ALWAYS BE CURATIVE
B. 2.BE PATIENT-CENTERED
C. 3.BE CONVENIENT FOR THE PROVIDER
D. 4.FOCUS ON THE COST OF THERAPY
ANSWER>>2
11. THE THERAPEUTIC GOALS WHEN PRESCRIBING INCLUDE(S):
A. 1.CURATIVE
B. 2.PALLIATIVE
C. 3.PREVENTIVE
D. 4.ALL OF THE ABOVE
ANSWER>>D
12. WHEN DETERMINING DRUG TREATMENT, THE NP PRESCRIBER SHOULD:
PHARMACOTHERAPEUTICS FOR ADVANCED PRACTICE NURSE
PRESCRIBERS SIXTH EDITION BY TERI MOSER WOO| WENDY L.
WRIGHT| ALL CHAPTERS INCLUDED( 1-57)|100% VERIFIED
ANSWERS| LATEST EDITION
PRINTED PDF| ORIGINAL DIRECTLY FROM THE PUBLISHER| 100% VERIFIED ANSWERS| DOWNLOAD
IMMEDIETLY AFTER THE ORDER
,Table of Contents
UNIT I. THE FOUNDATION ............................................................................................................................ 4
CHAPTER 1. THE ROLE OF THE NURSE PRACTITIONER AS PRESCRIBER .................................................... 4
CHAPTER 2. REVIEW OF THE BASIC PRINCIPLES OF PHARMACOLOGY ................................................... 23
CHAPTER 3. RATIONAL DRUG SELECTION ............................................................................................... 32
CHAPTER 4. LEGAL AND PROFESSIONAL ISSUES IN PRESCRIBING .......................................................... 36
CHAPTER 5. ADVERSE DRUG REACTIONS ................................................................................................ 39
CHAPTER 6. AN INTRODUCTION TO PHARMACOGENETICS ................................................................... 44
CHAPTER 7. NUTRITION AND NUTRACEUTICALS .................................................................................... 48
CHAPTER 8. HERBAL THERAPIES ............................................................................................................. 58
CHAPTER 9. CANNABIS............................................................................................................................ 66
CHAPTER 10. PHARMACOECONOMICS ................................................................................................... 74
UNIT II. PHARMACOTHERAPEUTICS WITH SINGLE DRUGS ........................................................................ 78
CHAPTER 11. DRUGS AFFECTING THE AUTONOMIC NERVOUS SYSTEM ................................................ 79
CHAPTER 12. DRUGS AFFECTING THE CENTRAL NERVOUS SYSTEM ...................................................... 90
CHAPTER 13. DRUGS AFFECTING THE CARDIOVASCULAR AND RENAL SYSTEMS................................. 102
CHAPTER 14. DRUGS AFFECTING THE RESPIRATORY SYSTEM .............................................................. 114
CHAPTER 15. DRUGS AFFECTING THE HEMATOLOGICAL SYSTEM ....................................................... 120
CHAPTER 16. DRUGS AFFECTING THE IMMUNE SYSTEM: IMMUNIZATIONS ....................................... 127
CHAPTER 17: DRUGS AFFECTING THE IMMUNE SYSTEM: IMMUNOMODULATORS ............................ 134
CHAPTER 18. DRUGS AFFECTING THE GASTROINTESTINAL SYSTEM .................................................... 150
CHAPTER 19. DRUGS AFFECTING THE ENDOCRINE SYSTEM: PANCREATIC HORMONES AND
ANTIDIABETIC DRUGS ........................................................................................................................... 155
CHAPTER 20. DRUGS AFFECTING THE ENDOCRINE SYSTEM: PITUITARY, THYROID, AND ADRENAL
DRUGS ................................................................................................................................................... 162
CHAPTER 21. DRUGS AFFECTING THE REPRODUCTIVE SYSTEM ........................................................... 179
CHAPTER 22. DRUGS AFFECTING THE BONES AND JOINTS .................................................................. 187
CHAPTER 23. DRUGS AFFECTING THE INTEGUMENTARY SYSTEM ....................................................... 195
CHAPTER 24. DRUGS USED TO TREAT BACTERIAL DISEASES ................................................................ 202
CHAPTER 25. DRUGS USED TO TREAT VIRAL, FUNGAL, AND PROTOZOAL INFECTIONS....................... 210
CHAPTER 26. DRUGS USED TO TREAT INFLAMMATORY PROCESSES ................................................... 220
CHAPTER 27. DRUGS USED TO TREAT EYE AND EAR DISORDERS ......................................................... 226
UNIT III. PHARMACOTHERAPEUTICS WITH MULTIPLE DRUGS ................................................................ 229
, CHAPTER 28. ANEMIA ........................................................................................................................... 229
CHAPTER 29. ANXIETY AND DEPRESSION ............................................................................................. 234
CHAPTER 30. ATTENTION DEFICIT HYPERACTIVITY DISORDER ............................................................. 239
CHAPTER 31. ASTHMA AND ALERGY..................................................................................................... 243
CHAPTER 32. CHRONIC OBSTRUCTIVE PULMONARY DISEASE.............................................................. 248
CHAPTER 33. CONTRACEPTION............................................................................................................. 259
CHAPTER 34. COVID-19: ACUTE AND CHRONIC .................................................................................... 263
CHAPTER 35. DERMATOLOGICAL CONDITIONS .................................................................................... 281
CHAPTER 36. DIABETES MANAGEMENT ............................................................................................... 286
CHAPTER 37. GASTROESOPHAGEAL REFLUX AND PEPTIC ULCER DISEASE .......................................... 297
CHAPTER 38. HEADACHES ..................................................................................................................... 302
CHAPTER 39. HEART FAILURE ............................................................................................................... 307
CHAPTER 40. HUMAN IMMUNODEFICIENCY VIRUS DISEASE AND ACQUIRED IMMUNODEFICIENCY
SYNDROME ........................................................................................................................................... 314
CHAPTER 41. MENOPAUSAL HORMONE THERAPY .............................................................................. 318
CHAPTER 42. HYPERLIPIDEMIA ............................................................................................................. 329
CHAPTER 43. HYPERTENSION ............................................................................................................... 335
CHAPTER 44. HYPERTHYROIDISM AND HYPOTHYROIDISM .................................................................. 341
CHAPTER 45. OBESITY ........................................................................................................................... 346
CHAPTER 46. PAIN MANAGEMENT: ACUTE AND CHRONIC PAIN ......................................................... 361
CHAPTER 47. PNEUMONIA ................................................................................................................... 366
CHAPTER 48. SEXUALLY TRANSMITTED DISEASES AND VAGINITIS....................................................... 369
CHAPTER 49. SUBSTANCE USE DISORDER............................................................................................. 375
CHAPTER 50. TUBERCULOSIS ................................................................................................................ 385
CHAPTER 51. UPPER RESPIRATORY INFECTION, PHARYNGITIS, SINUSITIS, OTITIS MEDIA, AND OTITIS
EXTERNA ............................................................................................................................................... 388
CHAPTER 52. URINARY TRACT INFECTION ............................................................................................ 392
UNIT IV. SPECIAL DRUG TREATMENT CONSIDERATIONS ......................................................................... 396
CHAPTER 53: WOMEN AS PATIENTS ..................................................................................................... 396
CHAPTER 54. MEN AS PATIENTS ........................................................................................................... 402
CHAPTER 55. PEDIATRIC PATIENTS ....................................................................................................... 405
CHAPTER 56. TRANSGENDERED CLIENTS AS PATIENTS ........................................................................ 409
CHAPTER 57. GERIATRIC PATIENTS ....................................................................................................... 415
,UNIT I. THE FOUNDATION
CHAPTER 1. THE ROLE OF THE NURSE PRACTITIONER AS PRESCRIBER
MULTIPLE CHOICE
IDENTIFY THE CHOICE THAT BEST COMPLETES THE STATEMENT OR ANSWERS THE QUESTION.
1. NURSE PRACTITIONER PRESCRIPTIVE AUTHORITY IS REGULATED BY:
A. THE NATIONAL COUNCIL OF STATE BOARDS OF NURSING
B. THE U.S. DRUG ENFORCEMENT ADMINISTRATION
C. THE STATE BOARD OF NURSING FOR EACH STATE
D. THE STATE BOARD OF PHARMACY
ANSWER>>C
2. THE BENEFITS TO THE PATIENT OF HAVING AN ADVANCED PRACTICE REGISTERED NURSE (APRN)
PRESCRIBER INCLUDE:
A. NURSES KNOW MORE ABOUT PHARMACOLOGY THAN OTHER PRESCRIBERS BECAUSE THEY TAKE IT
BOTH IN THEIR BASIC NURSING PROGRAM AND IN THEIR APRN PROGRAM.
B. NURSES CARE FOR THE PATIENT FROM A HOLISTIC APPROACH AND INCLUDE THE PATIENT IN
DECISION MAKING REGARDING THEIR CARE.
C. APRNS ARE LESS LIKELY TO PRESCRIBE NARCOTICS AND OTHER CONTROLLED SUBSTANCES.
D. APRNS ARE ABLE TO PRESCRIBE INDEPENDENTLY IN ALL STATES, WHEREAS A PHYSICIAN'S ASSISTANT
NEEDS TO HAVE A PHYSICIAN SUPERVISING THEIR PRACTICE.
ANSWER>>B
3. CLINICAL JUDGMENT IN PRESCRIBING INCLUDES:
A. FACTORING IN THE COST TO THE PATIENT OF THE MEDICATION PRESCRIBED
B. ALWAYS PRESCRIBING THE NEWEST MEDICATION AVAILABLE FOR THE DISEASE PROCESS
C. HANDING OUT DRUG SAMPLES TO POOR PATIENTS
D. PRESCRIBING ALL GENERIC MEDICATIONS TO CUT COSTS
ANSWER>>A
4. CRITERIA FOR CHOOSING AN EFFECTIVE DRUG FOR A DISORDER INCLUDE:
, A. ASKING THE PATIENT WHAT DRUG THEY THINK WOULD WORK BEST FOR THEM
B. CONSULTING NATIONALLY RECOGNIZED GUIDELINES FOR DISEASE MANAGEMENT
C. PRESCRIBING MEDICATIONS THAT ARE AVAILABLE AS SAMPLES BEFORE WRITING A
PRESCRIPTION
D. FOLLOWING U.S. DRUG ENFORCEMENT ADMINISTRATION GUIDELINES FOR
PRESCRIBING
ANSWER>>B
5. NURSE PRACTITIONER PRACTICE MAY THRIVE UNDER HEALTH-CARE REFORM BECAUSE OF:
A. THE DEMONSTRATED ABILITY OF NURSE PRACTITIONERS TO CONTROL COSTS
AND IMPROVE PATIENT OUTCOMES
B. THE FACT THAT NURSE PRACTITIONERS WILL BE ABLE TO PRACTICE
INDEPENDENTLY
C. THE FACT THAT NURSE PRACTITIONERS WILL HAVE FULL REIMBURSEMENT
UNDER HEALTHCARE REFORM
D. THE ABILITY TO SHIFT ACCOUNTABILITY FOR MEDICAID TO THE STATE LEVEL
ANSWER>>A
6. AN NP WOULD PRESCRIBE THE LIQUID FORM OF IBUPROFEN FOR A 6-YEAR-OLD CHILD BECAUSE:
A. DRUGS GIVEN IN LIQUID FORM ARE LESS IRRITATING TO THE STOMACH.
B. A 6-YEAR-OLD CHILD MAY HAVE PROBLEMS SWALLOWING A PILL.
C. LIQUID FORMS OF MEDICATION ELIMINATE THE CONCERN FOR FIRST-PASS EFFECT.
D. LIQUID IBUPROFEN DOES NOT HAVE TO BE DOSED AS OFTEN AS THE TABLET FORM
ANSWER>>B
7. IN DECIDING WHICH OF MULTIPLE DRUGS USED TO USE TO TREAT A CONDITION, THE NP CHOOSES
DRUG BECAUSE IT:
A. HAS SERIOUS SIDE EFFECTS AND IT IS NOT BEING USED FOR A LIFE-THREATENING CONDITION
B. WILL BE TAKEN TWICE DAILY AND WILL BE TAKEN AT HOME
C. IS EXPENSIVE, BUT COVERED BY HEALTH INSURANCE
D. NONE OF THESE ARE IMPORTANT IN CHOOSING A DRUG
ANSWER>>B
, 8. A CLIENT ASKS THE NP ABOUT THE DIFFERENCES IN DRUG EFFECTS BETWEEN MEN AND WOMEN.
WHAT IS KNOWNABOUT THE DIFFERENCES BETWEEN THE PHARMACOKINETICS OF MEN AND WOMEN?
A. BODY TEMPERATURE VARIES BETWEEN MEN AND WOMEN.
B. MUSCLE MASS IS GREATER IN WOMEN.
C. PERCENTAGE OF FAT DIFFERS BETWEEN GENDERS.
D. PROVEN SUBJECTIVE FACTORS EXIST BETWEEN THE GENDERS
ANSWER>>C
9. THE FIRST STEP IN THE PRESCRIBING PROCESS ACCORDING TO THE WORLD HEALTH ORGANIZATION
IS:
A. 1.CHOOSING THE TREATMENT
B. 2.EDUCATING THE PATIENT ABOUT THE MEDICATION
C. 3.DIAGNOSING THE PATIENT'S PROBLEM
D. 4.STARTING THE TREATMENT
ANSWER>>C
10. TREATMENT GOALS IN PRESCRIBING SHOULD:
A. 1.ALWAYS BE CURATIVE
B. 2.BE PATIENT-CENTERED
C. 3.BE CONVENIENT FOR THE PROVIDER
D. 4.FOCUS ON THE COST OF THERAPY
ANSWER>>2
11. THE THERAPEUTIC GOALS WHEN PRESCRIBING INCLUDE(S):
A. 1.CURATIVE
B. 2.PALLIATIVE
C. 3.PREVENTIVE
D. 4.ALL OF THE ABOVE
ANSWER>>D
12. WHEN DETERMINING DRUG TREATMENT, THE NP PRESCRIBER SHOULD:
